Invitae

CareDx led the Index for the month — the firm's shares rose 81 percent on the strength of its second quarter earnings report.

The company also entered into a sales agreement with Cowen and Company to offer up to $75 million of its common stock for sale.

Based on the strength of its quarterly financial performance, Invitae said it is now expecting annual revenues of between $135 million and $140 million for 2018.

Natera led the Index for the second month in a row after it announced that it intended to raise $75 million in a public stock offering.

With panel sequencing data for more than 143,000 individuals, researchers characterized intragenic copy number variants in hundreds of monogenic disease genes.

Though the Dow, the Nasdaq, and the Nasdaq Biotechnology Index all rose in May, they were outperformed by the GenomeWeb Index.

Based on the growth in test volume and revenue, the company increased its volume and revenue guidance for the year.

The program is open to anyone in the US or in Puerto Rico who is suspected of having SMA or needs confirmation of the disease via genetic testing.